IL1A and cancer: Studies have shown that interleukin-10, along with other interleukins such as IL-1 and IL-4, can activate pathways like NF-κB, contributing to cancer radioresistance [47,48]; therefore, strategies to inhibit IL-10 or its signalling pathways could enhance the efficacy of radiation therapy.